CN103648487B - 药物递送系统 - Google Patents

药物递送系统 Download PDF

Info

Publication number
CN103648487B
CN103648487B CN201280034770.7A CN201280034770A CN103648487B CN 103648487 B CN103648487 B CN 103648487B CN 201280034770 A CN201280034770 A CN 201280034770A CN 103648487 B CN103648487 B CN 103648487B
Authority
CN
China
Prior art keywords
coating
testosterone
drug delivery
core
active constituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280034770.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103648487A (zh
Inventor
约翰内斯·马蒂纳斯·马里亚·布勒默斯
安科·科内鲁斯·艾森斯
亨德里克·威廉·弗里亚林克
利德 莱昂纳德斯·赫拉尔杜斯·约瑟夫·德
Original Assignee
EB IP HYBRITABS BV
Emotional Brain BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EB IP HYBRITABS BV, Emotional Brain BV filed Critical EB IP HYBRITABS BV
Priority to CN201910244873.XA priority Critical patent/CN109908099B/zh
Publication of CN103648487A publication Critical patent/CN103648487A/zh
Application granted granted Critical
Publication of CN103648487B publication Critical patent/CN103648487B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280034770.7A 2011-05-13 2012-05-14 药物递送系统 Active CN103648487B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910244873.XA CN109908099B (zh) 2011-05-13 2012-05-14 药物递送系统

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11166091.6 2011-05-13
EP11166091 2011-05-13
EP11181165 2011-09-13
EP11181165.9 2011-09-13
EP11183732.4 2011-10-03
EP11183732 2011-10-03
PCT/NL2012/050336 WO2012158030A2 (en) 2011-05-13 2012-05-14 Drug delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910244873.XA Division CN109908099B (zh) 2011-05-13 2012-05-14 药物递送系统

Publications (2)

Publication Number Publication Date
CN103648487A CN103648487A (zh) 2014-03-19
CN103648487B true CN103648487B (zh) 2019-04-19

Family

ID=46197660

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280034770.7A Active CN103648487B (zh) 2011-05-13 2012-05-14 药物递送系统
CN201910244873.XA Active CN109908099B (zh) 2011-05-13 2012-05-14 药物递送系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910244873.XA Active CN109908099B (zh) 2011-05-13 2012-05-14 药物递送系统

Country Status (15)

Country Link
US (4) US9763884B2 (enExample)
EP (1) EP2709597A2 (enExample)
JP (1) JP6121990B2 (enExample)
KR (2) KR20140048882A (enExample)
CN (2) CN103648487B (enExample)
AU (1) AU2012256501B2 (enExample)
BR (1) BR112013029199B1 (enExample)
CA (1) CA2835845C (enExample)
EA (1) EA034288B1 (enExample)
IL (1) IL229425B (enExample)
MX (1) MX353623B (enExample)
PH (1) PH12013502325A1 (enExample)
SG (2) SG10201606751XA (enExample)
WO (1) WO2012158030A2 (enExample)
ZA (1) ZA201309156B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3003285T3 (en) * 2013-06-03 2022-04-04 Mcneil Ab Fast farmaceutisk dosisform til frigivelse af mindst to aktive farmaceutiske ingredienser i mundhulen
AU2014347357A1 (en) 2013-11-11 2016-06-16 Limoxifen B.V. Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
EP3248592A1 (en) 2016-05-25 2017-11-29 EB IP Hybritabs B.V. Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems
WO2019129360A1 (en) 2017-12-29 2019-07-04 Laxxon Medical Ag Drug delivery system
WO2019245975A1 (en) 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
KR102084602B1 (ko) * 2018-11-08 2020-03-04 주식회사 서흥 발포성 및 안정성이 향상된 구강 세정용 발포정
US12616702B2 (en) 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2024253526A1 (en) 2023-06-06 2024-12-12 Van Rooij Kim Compositions for treating a subject from sexual dysfunction
EP4773945A1 (en) * 2023-09-05 2026-07-15 Arletta Pharma Solutions Holding B.V. Drug delivery system for the treatment of female sexual interest and arousal disorder
WO2026052780A1 (en) * 2024-09-05 2026-03-12 Freya Pharma Solutions Holding B.V. Dual delivery pharmaceutical composition and method for determining dosage thereof
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
WO1993019741A1 (en) * 1992-03-31 1993-10-14 Benzon Pharma A/S A pharmaceutical formulation
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
CA2189355A1 (en) 1995-03-01 1996-09-06 Yasuo Onoda Imidazoquinazoline derivatives
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
AU5310898A (en) * 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
DE69814122T2 (de) 1997-10-09 2004-03-18 Dexcel Pharma Technologies Ltd. Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
IL141762A0 (en) * 1998-10-01 2002-03-10 Novartis Ag New oral formulations
US6977083B1 (en) * 1998-10-02 2005-12-20 Jenapharm Gmbh & Co. Kg Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
WO2003033025A2 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CN1946376A (zh) * 2004-03-25 2007-04-11 布里斯托尔-迈尔斯·斯奎布公司 包衣片剂组合物及其制法
CN101027061B (zh) 2004-05-11 2014-03-12 情感智能有限责任公司 药物制剂及其在治疗女性性功能障碍中的应用
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
CN101146521A (zh) * 2005-03-14 2008-03-19 太阳医药高级研究有限公司 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US20070003623A1 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN100551373C (zh) 2005-12-01 2009-10-21 北京华素制药股份有限公司 盐酸丁螺环酮缓/控释微丸
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
PL2457563T3 (pl) 2006-05-09 2017-09-29 Mallinckrodt Llc Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CA2660476C (en) * 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2009098697A1 (en) * 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
JP5777273B2 (ja) 2008-07-10 2015-09-09 大正製薬株式会社 不快な呈味を有する薬物を含有する製剤粒子
KR101412401B1 (ko) 2009-09-15 2014-06-25 팀 아카데미 오브 파마슈티컬 사이언스 삼투 펌프 제어 방출 정제 및 이의 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration

Also Published As

Publication number Publication date
JP6121990B2 (ja) 2017-04-26
MX2013013204A (es) 2014-06-06
US20170354605A1 (en) 2017-12-14
IL229425A0 (en) 2014-01-30
NZ618535A (en) 2016-03-31
IL229425B (en) 2020-05-31
US20210290551A1 (en) 2021-09-23
EA034288B1 (ru) 2020-01-24
US9763884B2 (en) 2017-09-19
PH12013502325A1 (en) 2014-02-10
SG194943A1 (en) 2013-12-30
KR102158948B1 (ko) 2020-09-24
AU2012256501A1 (en) 2013-12-19
SG10201606751XA (en) 2016-10-28
KR20190083369A (ko) 2019-07-11
CN109908099B (zh) 2021-10-29
US20240165032A1 (en) 2024-05-23
KR20140048882A (ko) 2014-04-24
EP2709597A2 (en) 2014-03-26
AU2012256501B2 (en) 2017-04-06
BR112013029199A8 (pt) 2018-02-06
WO2012158030A2 (en) 2012-11-22
CA2835845A1 (en) 2012-11-22
JP2014513685A (ja) 2014-06-05
NZ717187A (en) 2017-08-25
US20150056277A1 (en) 2015-02-26
WO2012158030A3 (en) 2013-04-18
EA201391689A1 (ru) 2014-05-30
US10966933B2 (en) 2021-04-06
BR112013029199A2 (pt) 2017-02-14
CN103648487A (zh) 2014-03-19
CN109908099A (zh) 2019-06-21
BR112013029199B1 (pt) 2022-02-08
ZA201309156B (en) 2015-02-25
CA2835845C (en) 2020-07-28
MX353623B (es) 2018-01-22

Similar Documents

Publication Publication Date Title
US20240165032A1 (en) Drug delivery system
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
US10821118B2 (en) Oral transmucosal drug delivery system
JP2013155190A (ja) ステロイドホルモンを含むタブレット
KR20200028403A (ko) 모발 성장을 촉진시키고, 탈모 또는 과도한 머리카락 빠짐의 치료
KR102542506B1 (ko) 바깥 층 또는 부분에 존재하는 테스토스테론 화합물을 가진 약물 전달 시스템을 제조하기 위한 방법 및 이러한 약물 전달 시스템
Kottke et al. Development and evaluation of a composite dosage form containing desmopressin acetate for buccal administration
Canadell-Heredia et al. Formulation and development of paediatric orally disintegrating carbamazepine tablets
JP5337430B2 (ja) 口腔内速崩壊錠
CN115989023A (zh) 多药物递送的系统和方法
Rai et al. Preparation and evaluation of oral dispersible formulations of amlodipine besylate
NZ618535B2 (en) Drug delivery system
NZ717187B2 (en) Drug delivery system
RU2537169C1 (ru) Фармацевтическая композиция, содержащая дезлоратадин (варианты)
EA052489B1 (ru) Жидкая композиция ингибиторов фосфодиэстеразы типа 5 (pde-5), способ ее получения и ее применение для лечения эректильных дисфункций

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: EB IP HIBORE TUBBS LLC

Free format text: FORMER OWNER: EMOTIONAL BRAIN B. V.

Effective date: 20150428

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150428

Address after: Holland Almere

Applicant after: EB IP Cibo Rita Buss Ltd

Address before: Holland Almere

Applicant before: Emotional Brain B. V.

GR01 Patent grant
GR01 Patent grant